Author(s)

Yeu-Tyng Lin¹, Yen-Chen Chen², Yu-Ting Peng³, Lujie Chen³, Jorn-Hon Liu², Fu-Li Chen³, Tao-Hsin Tung^3,4*

¹Department of Family and Community Medicine, Cheng-Hsin General Hospital, Taipei City.
²Department of Ophthalmology, Cheng-Hsin General Hospital, Taipei.
²Department of Ophthalmology, Cheng-Hsin General Hospital, Taipei City.
³Faculty of Public Health, College of Medicine, Fu-Jen Catholic University, Taipei City.
⁴Department of M edical Research and Education, Cheng-Hsin General Hospital, Taipei City.

Diabetic retinopathy (DR) is a well-characterized chronic ocular disorder that developed in nearly all diabetic patients in the long run. The knowledge of DR is crucial to manage this disorder when planning screening and preventive programs and identifying the appropriated therapeutic strategies among. Expectant management may represent a valid therapeutic approach depending upon the clinical manifestations of the disease and, in particular, on the changes over time. If early treatment of DR reduces the probability of severe stage or slows the progression of blindness, it might sufficiently reduce treatment costs in later years to offset the costs of screening and early treatment. In addition, whether screening for DR is worthwhile is contingent on whether subjects are willing to pay the eye screening program that would decrease the risk of photocoagulation. In this review we discuss epidemiology, management, and economic evaluation of screening of DR among type 2 diabetes.

Diabetic Retinopathy, Epidemiology, Economic Evaluation, Screening, Type 2 Diabetes

Lin, Y. , Chen, Y. , Peng, Y. , Chen, L. , Liu, J. , Chen, F. and Tung, T. (2015) Evidence-Based Medicine of Screening of Diabetic Retinopathy among Type 2 Diabetes: A Clinical Overview. Health, 7, 873-883. doi: 10.4236/health.2015.77103.